ClinicalTrials.gg
Active, not recruitingNCT05622136STRAT-aHCCUpdated Mar 27, 2026

Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma

A Phase 2 interventional study of Regorafenib Oral Product in Liver Cancer and Hepatocellular Carcinoma, sponsored by Instituto do Cancer do Estado de São Paulo. Active, not recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.

Primary conditionCarcinoma, HepatocellularRegistry: Liver NeoplasmsReclassifiedWhy we changed it
Registry
Liver Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Carcinoma, Hepatocellular
Why
  1. The study's listed conditions name Carcinoma, Hepatocellular, a narrower term within Liver Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Instituto do Cancer do Estado de São Paulo · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing regorafenib in Carcinoma, Hepatocellular — 7 open to participants now, 9 under way, none of them phase 3. regorafenib · Carcinoma, Hepatocellular.

Planned enrollment
13th of 22
28 · median 33
Started
2023
with 3 others
Phase 2
16 of 22
6 open now
Registered
16th of 22
by date
Lead sponsor
1 of 22
Instituto do Cancer do Estado de São Paulo

Among the 22 studies testing regorafenib in Carcinoma, Hepatocellular, this one is the 13th largest by planned enrollment, is one of 4 that started in 2023, is one of 16 in phase 2, and was the 16th registered.

Carcinoma, Hepatocellular

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 22 studies testing regorafenib in Carcinoma, Hepatocellular are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing regorafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The present protocol (STRAT-aHCC trial) aims to prospectively evaluate the tolerability, quality of life and efficacy of an alternative regimen of regorafenib in patients with advanced hepatocellular carcinoma (HCC) after progression to first-line. Patients will receive increasing dose of regorafenib in the first 2 treatment cycles (initial dose of 80mg, with weekly increments of 40mg up to 160mg in the first 2 treatment cycles). From the 3rd cycle on, the maximum tolerated dose during the first 2 cycles will be maintained. The maximum tolerated dose will be considered the highest dose in which the patient does not present grade ≥3 adverse events. The primary endpoint is the proportion of evaluable patients completing cycle 4. Radiologic response rate, quality of life, time to progression and overall survival will be evaluated as secondary endpoints.

Read the detailed description

In patients who are refractory to first-line treatment with sorafenib, regorafenib was tested in the phase III RESORCE study. In this study, a standard dose of 160mg/day was used (in cycles of 4 weeks, with 3 weeks on treatment and 1 week off) until tumor progression or limiting toxicity. Regorafenib was superior to placebo with a significant increase in overall survival and became a sequential treatment option.

However, regorafenib is associated with relevant adverse events such as fatigue, hand-foot reaction, diarrhea and hypertension. Such events are more frequent in the first 2 cycles. In the RESORCE trial, 54% of patients had adverse events requiring interruption or dose reduction, and treatment discontinuation was required in 10% of patients. This toxicity profile limits the wide adoption of this drug in clinical practice.

Dose escalation strategies for regorafenib have been evaluated in patients with colorectal cancer and have resulted in better tolerability with comparable efficacy. However, there are no prospective studies with alternative doses of regorafenib in patients with advanced HCC.

The present protocol (STRAT-aHCC trial) aims to prospectively evaluate the tolerability, quality of life and efficacy of an alternative regimen of regorafenib in patients with advanced HCC. Patients will receive increasing dose of regorafenib in the first 2 treatment cycles (initial dose of 80mg, with weekly increments of 40mg up to 160mg in the first 2 treatment cycles - Figure 1). From the 3rd cycle on, the maximum tolerated dose during the first 2 cycles will be maintained. The maximum tolerated dose will be considered the highest dose in which the patient does not present grade ≥3 adverse events. The primary endpoint is the proportion of evaluable patients completing cycle 4. Radiologic response rate, quality of life, time to progression and overall survival will be evaluated as secondary endpoints.

Medical visits will be carried out weekly in the first 2 treatment cycles and every 4 weeks after the 3rd cycle. Laboratory tests will be performed every 2 weeks during the first 2 cycles and every 4 weeks after the 3rd cycle. Response assessment by imaging exams will be performed every 8 weeks. Quality of life assessments will be performed every 4 weeks using the EuroQol EQ-5D-5L7 questionnaire. The planned sample size is 28 patients with an expected duration of 25-30 months.

03

Conditions studied

  • Liver Cancer
  • Hepatocellular Carcinoma

Browse trials for

Keywords

  • Regorafenib
  • Hepatocellular carcinoma
  • Dose
  • Tolerability
  • Quality of life
04

In context

Carcinoma, Hepatocellular Reclassified

3,653 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

This study's planned enrollment of 28 is below the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Instituto do Cancer do Estado de São Paulo is the lead sponsor of 91 studies on the registry; 21 are open to participants now.

Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older;
  2. Hepatocellular carcinoma with histological or cytological confirmation or that meet radiological criteria for the diagnosis of HCC21;
  3. BCLC-B stage not candidate for locoregional treatment or BCLC-C;
  4. Have been previously treated with at least 1 with sorafenib, levantinib, atezolizumab plus bevacizumab or other immunotherapy-based regimen;
  5. Have received the last dose of first-line systemic treatment between 2 and 6 weeks before starting study treatment;
  6. Recovery to baseline or ≤ grade 1 from toxicities related to any previous treatments, unless the adverse event is not as determined by the investigator (according to the (CTCAE) v522);
  7. Not having received previous treatment with regorafenib;
  8. A or B7 (in the absence of clinical ascites);
  9. as defined by the 1.1 criteria. Target lesions must not have undergone previous local or locoregional treatment (example: ablation, transarterial chemoembolization, radiotherapy or selective internal radiotherapy)
  10. Performance status: 0 or 1.
  11. Adequate hematologic, hepatic and renal functions as defined below:

    i. ≥ 8.5 g/dl ii. ≥ 1,000 /mm3 iii. count ≥ 50,000 /mm3 iv. Total \< 2.0 x upper limit of normality () v. or AST \<5 x LSN vi. (CrCI) ≥ 30 mL/min (according to Cockroft-Gault formula) vii. Serum albumin ≥ 2.8 mg/dl

  12. Ability to understand and comply with the treatment protocol.
  13. Informed consent form and clarification signed by the patient, impartial witness or legal representative.
  14. Sexually active patients of and their partners must agree to use highly effective methods of that result in a rate of less than 1% per year when used consistently and correctly throughout the study and 6 months after treatment discontinuation;
  15. Female participants of childbearing potential cannot be pregnant at screening.

Exclusion criteria

Exclusion Criteria:

  1. Fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma;
  2. Previous use of regorafenib;
  3. Hepatic encephalopathy or medication requirement to control hepatic encephalopathy in the last 60 days before randomization;
  4. ascites (ie, ascites that requires parcentesis or increased dose of diuretics) within 30 days prior to randomization.
  5. Patients who have received local therapies (ablation, transarterial chemomebolization or surgery) within 28 days prior to randomization. Radiation treatments with the aim of pain control of bone are allowed.
  6. Known or suspected or cranial epidural disease unless adequately treated with surgery or radiotherapy and stable for at least 8 weeks from randomization.
  7. Any participant who cannot be submitted neither to computed tomography (CT) nor magnetic resonance imaging (MRI) due to to contrast media used.
  8. The participant has an uncontrolled disease, or a significant complication in the last 28 days of randomization, such as:

    1. Cardiovascular disorders:

      • i. Class III or IV congestive heart failure as defined by the , unstable angina pectoris, or symptomatic arrhythmias;
      • ii. Uncontrolled hypertension (defined as systolic blood pressure greater than 160 mmgHg or diastolic pressure > 95 mmHg despite antihypertensive therapy);
      • iii. Stroke, myocardial ischemia, or any ischemic event within the 6-month period prior to randomization;
    2. Gastrointestinal disorders, including those associated with a high risk of perforation:

      • i: active peptic ulcer disease, inflammatory bowel disease, tumors invading the gastrointestinal tract, diverticulitis, cholecystitis, appendicitis, acute pancreatitis and cholangitis;
      • ii: Abdominal fistula, gastro-intestinal perforation or abdominal abscess in the last 6 months;
      • iii: Esophageal varices that have not been adequately treated or that have been incompletely treated with bleeding or high risk of bleeding. Participants treated with adequate endoscopic therapy with no bleeding in the past 6 months are eligible;
    3. Clinically detected hematuria, hematemesis, melena, hemoptysis (>2.5 ml) or other clinically significant bleeding within the last 3 months of randomization.
    4. Cavitating pulmonary lesion or known manifestation of endobronchial disease;
    5. Other clinically significant diseases, at the discretion of the attending physician.
  9. Majority surgery within 28 days of randomization. Minor surgeries within 10 days of randomization. Participants must have complete healing of the procedures prior to randomization;
  10. History of psychiatric illness that is likely to interfere with the ability to understand the study procedures;
  11. Pregnant or breastfeeding women;
  12. Inability to swallow pills;
  13. Known allergies to study drug components;
  14. Any other known active at the time of randomization or diagnosis of another malignancy within two years of randomization, except superficial skin carcinomas or low-grade localized tumors considered cured and not treated with systemic therapy.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Regorafenib

    Cycles 1 and 2: * Week 1: 80mg/day * Week 2: 120mg/day * Week 3: 160mg/day * Week 4: off-treatment Cycles 3 on (up to treatment discontinuation) * Weeks 1 to 3: Maximum dose tolerated daily, defined as the highest dose at which the patient had no adverse events grade ≥3 by CTCAE version 5.0 during cycles 1 and 2. * Week 4: off treatment * Dose adjustments may be required. Appendix 11.1 guide dose adjustments. Individual decisions at the occurrence of particular adverse events may be discussed individually within the study team and investigators. Treatment will be administered until any of the following events occur: * Both radiological and clinical progression according to definition of mRECIST or clinical deterioration that prevents treatment continuation according to the judgment of the attending physician * Limiting toxicity as defined by a grade 3 adverse event that does not resolve to grade \< 3 within 7 days; adverse event grade 4 or 5. * Subject decision.

    Drug: Regorafenib Oral Product

Interventions

07

What researchers measure

Primary outcomes

  1. Proportion of patients who complete 4 cycles of treatment

    Time frame: 4 months

Secondary outcomes

  1. Proportion of patients with disease control after 4 treatment cycles;

    Patients with partial response or stable disease after 4 cycles

    Time frame: 4 months

  2. Median overall survival: time from treatment initiation to death;

    Time from treatment initiation to death

    Time frame: 5 years

  3. Median progression-free survival: time from treatment initiation to progression or death

    Time from treatment initiation to progression or death

    Time frame: 5 years

  4. Score in the The 5-level EuroQol EQ-5D-5L questionnaire

    \- 0.532 (worst health state) and 1 (most optimal health state)

    Time frame: 5 years

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 352 non-industry phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 38 months is below that.

Counting every sponsor, half of 432 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2022
First posted
Nov 18, 2022
StartActual
Sep 10, 2023
Primary completionEst.
Nov 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05622136
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Responsible party
Leonardo Gomes da Fonseca (Principal Investigator,, Instituto do Cancer do Estado de São Paulo) — Principal investigator
First posted
Nov 18, 2022
Start date
Sep 10, 2023
Primary completion
Nov 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Mar 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Regorafenib

Start the discussion